Overview

Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease

Status:
Not yet recruiting

Trial end date:
2023-12-31

Target enrollment:
0

Participant gender:
All

Summary

The main goal of PD research is to develop disease-modifying drugs to delay or prevent the underlying neurodegenerative process. Levodopa, as the gold standard for PD treatment, is associated with the occurrence of motor complications. Many previous studies have confirmed that Stalevo can reduce the side effects of levodopa alone. Moreover, the effects of Stalevo on the treatment of PD patients have been extensively studied, but the efficacy of Stalevo in early PD patients has been less studied. Therefore, it is necessary to further study the treatment of early PD with Stalevo, and observe whether increasing the number of medication can reduce the occurrence of dyskinesis. The research results will help to deepen the understanding of Stalevo in the treatment of early PD and its clinical efficacy.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Treatments:

Carbidopa
Entacapone
Levodopa

Criteria

Inclusion Criteria:

- Volunteer to participate in the trial and sign the informed consent

- The enrolled patients were 30 to 70 years old, diagnosed as primary Parkinson's
disease according to the 2015 MDS Parkinson's disease diagnostic criteria, H-Y grade
<3, and the onset time was less than 5 years

- Patients can take stable dopamine receptor agonists or other anti-Parkinson's disease
drugs (drugs have not been adjusted in the past 4 weeks), and have not used amantadine
or entacapone within 1 year.

Exclusion Criteria:

- Atypical Parkinsonism and Secondary parkinsonism